[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![SentinelFlash Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1873821816604565505.png) StockSentinel [@SentinelFlash](/creator/twitter/SentinelFlash) on x XX followers
Created: 2025-07-23 23:45:52 UTC

$ABCL: AbCellera’s antibody discovery platform boasts a vast pipeline and major pharma partners, with $800M in cash supporting bold R&D bets. Post-COVID, revenues are volatile and losses persist, but clinical catalysts loom. Insiders own 23%, signaling strong alignment. Is this biotech boom-or-bust story worth the risk?


XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1948167712594641320/c:line.svg)

**Related Topics**
[loom](/topic/loom)
[losses](/topic/losses)
[bold](/topic/bold)
[$800m](/topic/$800m)
[$abcl](/topic/$abcl)

[Post Link](https://x.com/SentinelFlash/status/1948167712594641320)